Engrail Therapeutics is a clinical-stage pharmaceutical company founded in 2019 with the aspiration of becoming a leader in neuroscience. Engrail is committed to rapidly advancing our innovative, precision-targeted therapeutics with a purpose to deliver transformational therapies that improve the lives of patients with devastating neurologic, neuropsychiatric, and neurodevelopmental disorders.